A biotech company reports that an experimental treatment elongated its CEO’s telomeres.
November 16, 1987|
T he debate over complete sequencing of the human genome continues at a fever pitch. Indeed, this sequencing has become the biologists’ cause celebre for the waning years of this decade. While many have spoken forcefully in favor of this sequencing, the voices of opposition, at least in public, have been more muted. Many think it foolhardy and retrogressive to argue against a project that promises to yield a mountain of new data. With the U.S. Department of Energy and the National Inst